To recover its lead in obesity drugs, the Danish giant is transforming itself
Catch up on global daily news
Compelling long reads
Future-gazing analysis, predictions and speculation
Tune into captivating conversations
Watch engaging short films
To recover its lead in obesity drugs, Novo Nordisk is transforming itself
To recover its lead in obesity drugs, Novo Nordisk is transforming itself
All three have suffered the curse of overnight success
Lars Fruergaard Jørgensen on how society can pull together to avoid a health and economic catastrophe
New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective and…
Researchers point to a grocers’ favourite
